Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03872206 · ClinicalTrials.gov registry record · Phase 1
Study of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression
A Phase 1 study, sponsored by Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- Completed
- Registry status
- Phase 1
- Development phase
- 95
- Enrollment target
NCT03872206 is a Phase 1 study that has completed, run by Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA). The registered enrollment target is 95 participants.
The verdict
NCT03872206, a Phase 1 study, has completed, sponsored by Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 95 participants
- Enrollment target
Study Summary
An open-label, Phase 1/2a study of HPN536 as monotherapy to assess the safety, tolerability and PK in patients with advanced cancers associated with mesothelin expression.(Phase 2 portion of the study was not conducted.)
Interventions
- BIOLOGICAL HPN536 Fixed IV 6 to 560 ng/kg
- BIOLOGICAL HPN536 1 Prime Step IV 600-1200 ng/kg Target
- BIOLOGICAL 2 Prime Step IV 900-14000 ng/kg Target
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2019-04-16 |
| Est. Completion | 2023-01-04 |
| Phase | Phase 1 |
Sponsor
Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)4 total trials
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03872206
The ClinicalTrials.gov registry entry for NCT03872206 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 95 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which HPN536 Fixed IV 6 to 560 ng/kg is the first listed.
NCT03872206 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03872206 about?
NCT03872206 is a clinical study titled "Study of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression". An open-label, Phase 1/2a study of HPN536 as monotherapy to assess the safety, tolerability and PK in patients with advanced cancers associated with mesothelin expression.(Phase 2 portion of the study was not conducted.)
What is the current status of trial NCT03872206?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 95 participants. The study started on 2019-04-16. Estimated completion is 2023-01-04.
What interventions are being tested in trial NCT03872206?
The interventions under investigation include: HPN536 Fixed IV 6 to 560 ng/kg (BIOLOGICAL), HPN536 1 Prime Step IV 600-1200 ng/kg Target (BIOLOGICAL), 2 Prime Step IV 900-14000 ng/kg Target (BIOLOGICAL).
Who is sponsoring clinical trial NCT03872206?
This trial is sponsored by Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.